The US Prevalence of ATTR-CM

Please use landscape view or desktop screen to view the content.

The US Prevalence of ATTR-CM Is Estimated to be 100-150K Based on Assumptions From Currently Available Literature^1-10

Transthyretin Amyloid Cardiomyopathy > ATTR-CM > Prevalence > The US Prevalence of ATTR-CM

Wild-type ATTR

US males >60¹

7.4% with heart failure (HF)
based on NHANES²

47% with preserved ejection
fraction (HFpEF)³

10% with wild-type ATTR-CM^4,5

Scale up for females, assuming 10:1
male-to-female ratio^6,7

~32.1M
~2.3M
~1.1M
~111K
~122K

Hereditary ATTR

US African
Americans >60¹

3.43% with V122I
mutation⁸

8% mutation penetrance
(incident heart failure)⁹

~2k scale up for other mutations with
cardiac phenotype¹⁰

~5.3M
~182K
~15K
~17K

~139K

ATTR-CM: Transthyretin amyloid cardiomyopathy; HFpEF: Heart failure with preserved ejection fraction; NHANES: National Health and Nutrition Examination Survey; US: United States.

References:

US Census Bureau, Population Division. Available at: https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.
xhtml?pid=PEP_2017_PEPAGESEX&prodType=table. Accessed January 12, 2022.
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association [published correction appears in Circulation. 2017 Mar 7;135(10):e646] [published correction appears in Circulation. 2017 Sep 5;136(10):e196.]. Circulation. 2017;135(10):e146-e603.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-259.
González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-2594.
Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113-122.
Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2(2):e000098.
Grogan M, Scott CG, Kyle RA, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System [published correction appears in J Am Coll Cardiol 2017 Jun 13;69(23):2882]. J Am Coll Cardiol. 2016;68(10):1014-1020.
Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African- Americans. Amyloid. 2015;22(3):171-174.
Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372(1):21-29.
Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829-837.